GAMCO Investors’s Niagen Bioscience NAGE Stock Holding History

GAMCO Investors’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$232K	Sell	72,700 -92,300	-56%	-$375K	﹤0.01%	886
2026 Q1	$728K	Buy	165,000 +4,000	+2%	+$21.6K	0.01%	680
2025 Q4	$1.02M	Buy	161,000 +35,550	+28%	+$247K	0.01%	646
2025 Q3	$1.17M	Sell	125,450 -3,350	-3%	-$33.8K	0.01%	617
2025 Q2	$1.86M	Sell	128,800 -14,000	-10%	-$138K	0.02%	544
2025 Q1	$985K	Buy	142,800 +1,800	+1%	+$11.3K	0.01%	570
2024 Q4	$748K	Sell	141,000 -2,150	-2%	-$11.8K	0.01%	630
2024 Q3	$522K	Sell	143,150 -90,000	-39%	-$283K	0.01%	689
2024 Q2	$637K	Sell	233,150 -30,700	-12%	-$103K	0.01%	666
2024 Q1	$918K	Buy	263,850 +2,200	+0.8%	+$4.07K	0.01%	601
2023 Q4	$374K	Buy	261,650 +1,800	+0.7%	+$2.51K	﹤0.01%	724
2023 Q3	$379K	Buy	259,850 +54,500	+27%	+$85.1K	﹤0.01%	710
2023 Q2	$322K	Buy	205,350 +28,800	+16%	+$43K	﹤0.01%	741
2023 Q1	$270K	Buy	+176,550	New	+$314K	﹤0.01%	787

Other funds holding NAGE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

GAMCO Investors's NAGE Position: Q2 2026 in Review

GAMCO Investors reduced its Niagen Bioscience (NAGE) stake by 56% in Q2 2026, selling an estimated $375K and leaving 72,700 shares worth $232K. The position accounts for ﹤0.01% of the portfolio, ranked #886.

GAMCO Investors first reported a position in NAGE in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.86M in Q2 2025. 140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

GAMCO Investors held 72,700 shares of Niagen Bioscience worth $232K as of Q2 2026.
GAMCO Investors sold 92,300 Niagen Bioscience shares in Q2 2026, an estimated $375K.
Niagen Bioscience made up ﹤0.01% of GAMCO Investors's portfolio in Q2 2026, its #886 holding.
GAMCO Investors first reported a position in Niagen Bioscience in Q1 2023 and has held it in 14 quarters since.
GAMCO Investors's Niagen Bioscience position peaked at $1.86M in Q2 2025.
140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on GAMCO Investors's 13F filing for Q2 2026, filed 12 Aug 2026.